The ige-mediated cutaneous late-phase reaction

Urticaria and Angioedema

Volumn , Issue , 2004, Pages 119-140

  Samolitis, Nancy ^a   Leiferman, Kristin M ^a   Gleich, Gerald J ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3042721283     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (77)

1. Blackley CH. Experimental researches on the causes and nature of Catarrhus Aestivus (hay fever or hay asthma). 1873; Bailliere, Tindell and Cox, reprinted by Dawson’s of Pall Mall, London. 1959:77-81.
2. Prausnitz C, Küstner H. Studien uber Uberempfindlichkeit. Centralbl Bakteriol Abt. I Orig 1921; 86: 160.
3. Cooke RA. Studies in specific hypersensitiveness. IX. On the phenomenon of hyopsensitization (the clinically lessened sensitiveness of allergy). J Immunol 1922; 7:219
4. Vaughn WT. A study of eczema as an allergic phenomenon. South Med J 1924; 17:749.
5. Herxheimer H. The late bronchial reaction in induced asthma. Int Arch Allergy Appl Immunol 1952; 3:323.
6. Pepys J, Turner-Warwick M, Dawson PL, Hinson KFW. Arthus (type III) skin test reactions in man. Clinical and immunopathological features, in Excerpta Medica International Congress Series. Allergology, Proceedings of the Sixth Congress of the International Association of Allergology 1968; 162:221.
7. Dolovich J, Little DC. Correlates of skin test reactions to Bacillus Subtilis enzyme preparations. J Allergy Clin Immunol 1972; 49:43.
8. Dolovich J, Hargreave FE, Chalmers R, Shier KJ, Gauldie J, Beinenstock J. Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 1973; 52:38.
9. Solley GO, Gleich GJ, Jordan RE, Schroeter AL. Late phase of the immediate wheal and flare skin reaction: its dependence on IgE antibodies. J Clin Invest 1976; 58:408.
10. Gleich GJ. The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? J Allergy Clin Immunol 1982; 70(3): 160-169.
11. Charlesworth EN, Iliopoulos O, MacDonald SM, Kagey-Sobotka A, Lichtenstein LM. Cells and secretagogues involved in the human late-phase response. Int Arch Allergy Appl Immunol 1989; 88(1-2):50-53.
12. Zweiman B. The late-phase reaction: role of IgE, its receptor and cytokines. Curr Opin Immunol 1993; 5(6):950-955.
13. Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. Allergy Clin Immunol 2000; 105(5): 847-859
14. Peters SP, Zangrilli JG, Fish JE. Late phase allergic reactions In: Middleton E Jr, Reed CE, Ellis EF, Atkinson NF Jr, Busse WW, Yunginger JW, eds. Allergy. Principles and Practice. 5th ed. St. Louis: Mosby, 1998:342-355.
15. Zetterstrom O. Dual skin test reactions and serum antibodies to subtilisin and Aspergillus fumigalus extracts. Clin Allergy 1978; 8:77.
16. Shaikh W, Umemoto L, Pootbullil J, Hargreave FE, Dolovich J. Relative refractory state for late cutaneous allergic responses. J Allergy Clin Immunol 1977: 60:242.
17. Leiferman KM, Fujisawa T, Gray B, Gleich GJ. Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous late phase reaction. Lab Invest 1990; 62:579.
18. Ying S. Meng Q, Barata LT, Kay AB. Macrophage inflammatory protein-IO’ and C-C chemokine receptor-I in allergen-induced skin late-phase reactions: relationship to macrophages. neutrophils, basophils, eosinophils and T Iymphoctyes. Clin Exp Allergy 2001; 31:1724
19. Frew AJ, Kay AB. The relationship between CD4+ lymphocytes, activated eosinophils and the magnitude of the allergen-induced late phase skin reaction in man. J Immunol I988: 141:4158.
20. Irani AMA, Huang C, Xia HZ, Kepley C, Nafie A, Fouda ED, Craig S, Zweiman B, Schwartz L. Immunohistochemical detection of human basophils in late-phase skin reactions. J Allergy Clin Immunol 1998; 101:354.
21. Macfarlane AJ, Kon OM, Smith SJ, Zeibecoglou K, Khan N, Barata LT, McEuen AR, Buckley MG, Walls AF, Meng Q, Humbert M, Barnes NC, Robinson DS, Ying S, Kay AB. Basophils. eosinophils, and mast cells in atopic and nona topic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol 2000; 105: 199
22. Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, Walls AF, Askenase PW, Kay AB, C-C chemokines in allergen-induced latephase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationshiop to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 163:3976
23. Kinet JP. The high-affinity receptor for IgE. Curr Opin Immunol 1990: 2:499.
24. Segal OM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit for mast cell degranulation. Proc Natl Acad Sci USA 1977: 74:2993.
25. Paton, WDM. Compound 48/80: a potent histamine liberator. Br J Pharmacol Chemother 1951; 6:499.
26. Stalenheim G, Zetterström O. Late cutaneous allergic reactions without the participation of IgE. Monogr. Allergy 1979: 14:264
27. Tannenbaum S, Oertel H, Henderson W, Kaliner M. The biologic activity of mast cell granules. r Elicitation of inflammatory responses in rat skin. J Immunol 1980; 125(1):325-335
28. Smith JA, Mansfield LE, De Shazo RD, Nelson HS. The biologic activity of mast cell granules. III. Purification of inflammatory factors of anaphylaxis (IF-A) responsible for causing late-phase reactions. J Immunol 1981; 127:1398
29. Oertel H, Kaliner M. The biologic activity of mast cell granules in rat skin: effects of adrenocorticosteroids on late-phase inflammatory responses induced by mast cell granules. J Allergy Clin Immunol 1981: 68(3):138-4525.
30. Oertel HL, Kaliner M. The biologic activity of mast cell granules. III Purification of inllammatory factors of anaphylaxis (IF-A) responsible for causing late phase reactions. J Immunol 1981; 127(4):1398-1402.
31. Lemanske RF Jr, Joiner K, Kaliner M. The biologic activity of mast cell granules. IV. The effect of complement depletion on rat cutaneous late phase reactions. J Immunol 1983; 130(4):1881-1884.
32. Lemanske RF Jr, Barr L, Guthman DA, Kaliner M. The biologic activity of mast cell granules. V. The effects of antihistamine treatment on rat cutaneous early- and late-phase allergic reactions. J Allergy Clin Immunol 1983; 72(1): 94-99.
33. Lemanske RF Jr, Guthman DA, Oertel H, Barr L, Kaliner M. The biologic activity of mast cell granules. VI. The effect of vinblastine-induced neutropenia on rat cutaneous late phase reactions. J Immunol 1983; 130(6): 2837-2842
34. Lemanske RF Jr, Guthman DA, Kaliner M. The biologic activity of mast cell granules. VII. The eAect of anti-neutrophil antibody-induced neutropenia on rat cutaneous late phase reactions. J Immunol 1983; 131(2):929-933.
35. Lemanske RF Jr, Esser B, Kopp D, Asperheim M, Junk P, Tashoff T. The biologic activity of mast cell granules. VIII. In vivo and in vitro characterization of mast cell granule-derived inflammatory factors involved in rat late-phase reactions J Allergy Clin Immunol 1987; 79(1):32-39.
36. Naclerio RM, Proud D, Togias AA, Adkinson NF, Myers DA, Kagey Sobotka A, Plaut M, Norman PS, Lichtenstein LM. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313:365.
37. Charlesworth EN, Hood AF, Soter NA, Kagey-Sobotka A. Norman PS, Lichtenstein LM. The cutaneous late phase response to allergen: mediator release and inflammatory cell infiltration. J Clin Invest 1989; 83:1519.
38. Zweiman B, Von Allmen C. Temporal patterns of mediator release during developing cutaneous late-phase reactions. Clin Exp Allergy 2000; 30:856.
39. Lorenz W, Doenicke A. Histamine release in clinical conditions. Mt Sinai J Med 1978; 45:357
40. Juhlin L, Michaelsson G. Cutaneous reactions to kallikrein, bradykinin and histamine in healthy subjects and patients with urticaria. Acta Derm Venereol 1969; 49:26
41. Smith JA, Mansfield LE, deShazo RD, Nelson HS. An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reactions to allergen. J Allergy Clin Immunol 1980; 65:185.
42. de Weck AL, Derer T, Bischoff SC. Takafuji S. The effect of tertenadine on the immediate and late-phase reactions mediated by immunoglobulin E. Int Arch Allergy Immunol 1993; 101:326-332.
43. Schwartz LB, Atkins PC, Bradford TR. Release of tryptase together with histamine during the immediate cutaneous response to allergen. J Allergy Clin Immunol 1987; 80:850
44. Rice KD, Tanaka RD. Katz BA, Numerof RP, Moore WR. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Res 1998; 4:381-396
45. Oh SW, Pae CL Lee DK, Jones F, Chiang GK, Kim HO, Moon Sh. Cao B, Ogbu C, Jeong KW, Nakanishi H, Kahn M, Chi EY, Henderson WR Jr, Tryptase inhibition blocks inflammation in a mouse asthma model. J Immunol 2002; 15: 1992-2000.
46. Krishna MT, Chauhan A, Little L, Sampson K, Hawksworth R, Mant T, Djukanovic R, Lee T, Holgate S. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001; 107:1039-1045.
47. Pienkowski MM, Adkinson NF, Plaut M, Norman PS, Lichtenstein LM. Prostaglandin D2 and histamine during the immediate and late phase components of allergic cutaneous response. J Allergy Clin Immunol 1988; 8295.
48. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol 1983; 80: 115.
49. Dorsch W, Ring J, Strasser T, Weber PC. Detection on immunoreactive leukotrienes in skin blister fluid after allergen testing in patients with late cutaneous reactions. Int Arch Dermatol 1985; 277:400.
50. Roquet A, Dahlen B, Kumlin M, Ihre E, Anstren G, Binks S. Dahlen SE. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155(6): 1856-1863.
51. Henderson WR Jr. Eiconsanoids and platelet-activating factor an allergic respiratory diseases. Am Rev Respir Dis 1991; 143:S86-S90.
52. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr, Effect of recombinant human platelet-activating factor-acetylhydrolase on allergeninduced asthmatic responscs. Am J Respir Crit Care Med 2000; 162:523-527.
53. Barata LT, Ying S, Meng Q, Barkans J, Rajakulasingam K, Durham SR, Kay AB. IL-4 and IL-5 positive T Iymphoctyes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects. J Allergy Clin Immunol 1998; 101:222.
54. Kimura Y, Pawankar R, Aoki M, Niimi Y, Kawana S. Mast cells and T cells in Kimura’s disease express increased levels of interleukin-4, interleukin-5, eotaxin and RANTES. Clin Exp Allergy 2002: 32(12): 1787-1793.
55. Alam R, Grant JA, The chemokines and the histamine-releasing factors: modulation of function of basophils, mast cells and eosinophils. Chem Immunol 1995; 61:148.
56. Nakajima H, Loegering DA, Kita H, Kephart GM, Gleich GJ. Reactivity of monoclonal antibodies EG1 and EG2 with eosinophils and their granule proteins. J Leukoc Biol 1999: 66:447-454.
57. Kita H, Gleich GJ, The eosinophil structure and functions. In: Kaplan AP, ed. The Immune System and Inflammation. 2nd ed. Philadelphia: WB Saunders, 1997: 148-177.
58. Sur S, Adolphson CR, Gleich GJ. Eosinophils: biochemical and cellular aspects. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW. eds. Allergy: Principles and Practice. Vol. 1. 4 ed. St Louis: Mosby. 1993:169-200.
59. Gounni AS, Gregory B, Nutku E. Interleukin-9 enhances inlerleukin-5 receptor expression, diAerentiation, and survival of human eosinophils. Blood 2000: 96:2163.
60. Kita H, Kaneko M, Bartemes KR, Weiler DA, Schimming AW, Reed CE, Gleich GJ. Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 1999; 162:6901-6911.
61. Seminario MC, Saini SS. MacGlashan DW Jr, Bochner BS. Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol 1999; 162(11):6893-6900.
62. Leiferman KM, Loegering DA, Gleich GJ. Production of wheal-and-flare skin reactions by eosinophil granule proteins. Clin Res 1984; 32:598A.
63. Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O’Connell EJ, Kohler PF. Episodic angioedema associated with eosinophilia. N Engl J Med 1984; (310): 1621-1626.
64. Borish L, Rosenwasser LJ. Cytokines in Allergic Inflammation. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF, Yunginger JW. Busse WW, eds. Allergy: principles and practice. Vol. 1. 5th ed. St. Louis: Mosby, 1998:108-119
65. Shalit M, Campbell DE, von Allmen C, Atkins PC, Douglas SD, Zweiman B. Cellular inflammatory responses in human allergic skin reactions. J Allergy Clin Immunol 1987; 80:87.
66. Bochner BS, Charlesworth EN, Lichtenstein LM. Interleukin-1 is released at sites of" human cutaneous allergic reactions. J Allergy Clin Immunol 1990; 86:830
67. Lee CE, Neuland ME, Teaford HG. Jnterleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. J Allergy Clin Immunol 1992; 89:1010
68. Ying S, Meng Q. Kay AB, Robinson DS. Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-pbase reaction: relationships to eosinopbils, mast cells and T lymphocytes. Clin Exp Allergy 2002; 32:866.
69. McKenzie ANJ, Culpepper JA, De Waal Malefyt R, Briere F, Punllonell J, Aversa G, Sato A, Dang W, Cocks BG, Menon S, de Vries JE, Banchereau J, Zurawski G. Interleukin-13, a T-cell derived cytokille tbat regulates human monocyte and B cell function. Proc Natl Acad Sci USA 1993; 90:3730
70. McKenzie ANJ, Li X, Largaespada DA. Sato A, Kaneda A, Zurawski SM. Doyle EL, Milatovich A, Francke U, Copelan NG, Jenkins NA, Zuraski G. Structural comparison and chromosomal localization of human and mouse IL-13 gene. J Immunol 1993: 150:5436.
71. Minty A, Chalon P, Derocq JM, Dumont X, Guillemont JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993: 362:248.
72. Bochner BS, Klunk DA, Sterbinsky SA, Coffman R L, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-I expression in human endothelial cells. J Immunol 1995; 154:799.
73. Ying S, Meng Q, Barata LT, Robinson DS, Durham SR, Kay AB. Associations between IL-13 and IL-4 (mRNA and protein). vascular cell adhesion molecule 1 expression, and the infiltration or eosinophils, macrophages, and T cells in allergen-induced late-phase cutaneous reactions in atopic subjects. J Immunol 1997; 158:5050
74. Collins PD. Marleau S, Griffiths-Johnson DA, Jose PR, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995; 182: 1169.
75. Nielsen PN, Skov PS, Poulsen LK, Schmelz M, Petersen LJ. Cetirizine inhibits skin reactions but not mediator release in immediate and developing latephase allergic cutaneous reactions. A double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31:1378.
76. Gronneberg R, Strandberg K, Stalenheim G, Zetlerstrom O. Effect in man or anti-allergic drugs on the immediate and late phase cutaneous allergic reaction induced by anti-IgE. Allergy 1978; 36: 193.
77. Peters SP, Zangrilli JG. Fish JE Late phase allergic reactions. In: Middleton E Jr. Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. Allergy: Principles and Practice. Vol 1. 5th ed. St. Louis: Mosby. 1998:108-119.